Trinity Biotech plc 美股招股说明书（2026年2月17日版）

TRINITY BIOTECH PLCSecondary offering of up to55,890,900 American Depositary Sharesrepresenting1,117,818,000 Ordinary Shares This prospectus supplement updates and supplements the information contained in the prospectus dated January 23, 2026 (asmay be supplemented or amended from time to time, the “Prospectus”), which forms a part of our Registration Statement on Form F-1(Registration Statement No. 333-292753), with information contained in our Report on Form 6-K, which was filed with the Securities The prospectus, as it may be amended or supplemented from time to time, relates to the offer and resale by the Selling Our ADSs are listed for trading on the Nasdaq Global Select Market under the symbol “TRIB.” The last reported sale price of You should read the Prospectus, this prospectus supplement and any additional prospectus supplement or amendment Our business and an investment in our ADSs involve significant risks. These risks are described under the caption“Risk Factors” beginning on page 5 of the Prospectus and any other risk factors contained in any applicable prospectus Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved ofthese securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal The date of this prospectus supplement is February 17, 2026. F O R M6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16UNDER THE SECURITIES EXCHANGE ACT OF 1934 TRINITY BIOTECH PLC (Name of Registrant) IDA Business ParkBray, Co. Wicklow, Ireland EXPLANATORY NOTE On February 11, 2026, the Company issued a press release announcing it had received a notice from the Nasdaq Stock Market LLC(“Nasdaq”) that the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), requiring that listed securities maintain aminimum bid price of US $1.00 per share, based on the closing bid price of the Company’s American depositary shares (“ADSs”)for the last 30 consecutive business days. The Company has a period of 180 calendar days, or until August 10, 2026to regain EXHIBIT INDEX 99.1Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Nasdaq Minimum BidPrice Requirement SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on TRINITY BIOTECH PLCTrinity Biotech plc(Registrant)By: /s/ Paul Murphy Date: February 13, 2026